163 related articles for article (PubMed ID: 19827430)
21. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone.
Boxall EH; Sira J; Ballard AL; Davies P; Kelly DA
J Med Virol; 2006 Jul; 78(7):888-95. PubMed ID: 16721856
[TBL] [Abstract][Full Text] [Related]
23. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
24. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
26. [Autoimmune hepatitis--a rare cause of elevated transaminases].
Berdal JE; Rydning A
Tidsskr Nor Laegeforen; 1998 Nov; 118(29):4522-3. PubMed ID: 9889637
[TBL] [Abstract][Full Text] [Related]
27. Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better?
Koksal AR; Alkim H; Boga S; Ergun M; Bayram M; Ozguven BY; Alkim C
Am J Ther; 2016; 23(2):e429-38. PubMed ID: 25650531
[TBL] [Abstract][Full Text] [Related]
28. [Etiology of increased liver values from alcohol to hemochromatosis. Many roads lead to cirrhosis].
Bischoff A
MMW Fortschr Med; 2011 Mar; 153(13):22-3. PubMed ID: 21638810
[No Abstract] [Full Text] [Related]
29. [Serological and pathological features of drug-induced liver injury and autoimmune hepatitis].
Jiang ZL; Li P; Wang JL; Yang QH; Liu YG; Shi RF; Mi YQ
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):810-816. PubMed ID: 27978925
[No Abstract] [Full Text] [Related]
30. The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection.
Lee J; Kim MY; Kang SH; Kim J; Uh Y; Yoon KJ; Kim HS
Br J Biomed Sci; 2018 Jul; 75(3):128-132. PubMed ID: 29893189
[TBL] [Abstract][Full Text] [Related]
31. [HIV and hepatitis C coinfection].
Stoehr A; Brinkmann K; Sabranski M
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():54-5, 57. PubMed ID: 19024919
[No Abstract] [Full Text] [Related]
32. Activity of chronic hepatitis. Correlation of clinical, biochemical and histological parameters in 32 cases.
Gayotto LC; Strauss E; Alves VA; da Silva LC
Rev Inst Med Trop Sao Paulo; 1983; 25(6):288-93. PubMed ID: 6200913
[No Abstract] [Full Text] [Related]
33. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.
Ziol M; Nhieu JT; Roudot-Thoraval F; Métreau JM; Deugnier Y; Dhumeaux D; Zafrani ES
J Hepatol; 1996 Dec; 25(6):833-41. PubMed ID: 9007710
[TBL] [Abstract][Full Text] [Related]
34. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
[TBL] [Abstract][Full Text] [Related]
35. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy/prophylaxis with interferon and ribavirin for recurrent hepatitis C after liver transplantation: long-term effects on graft function and morphology.
Kornberg A; Hommann M; Tannapfel A; Grube T; Schotte U; Scheele J
Transplant Proc; 2002 Sep; 34(6):2259-60. PubMed ID: 12270389
[No Abstract] [Full Text] [Related]
37. Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature.
Chaiteerakij R; Sanpawat A; Avihingsanon A; Treeprasertsuk S
World J Gastroenterol; 2019 Sep; 25(35):5388-5402. PubMed ID: 31558881
[TBL] [Abstract][Full Text] [Related]
38. Nutmeg liver, fever and elevated liver enzymes in a young man.
Gavrić A; Dežman R; Ranković B; Ribnikar M; Štabuc B
Gut; 2019 Oct; 68(10):1773-1837. PubMed ID: 30700542
[No Abstract] [Full Text] [Related]
39. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection.
Karabay O; Tuna N; Esen S;
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1296-301. PubMed ID: 22825647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
